Download PDF
Pharmacopsychiatry 2009; 42(1): 29-34
DOI: 10.1055/s-0028-1100425
Original Paper

© Georg Thieme Verlag KG Stuttgart · New York

Effects of Six Second Generation Antipsychotics on Body Weight and Metabolism – Risk Assessment and Results from a Prospective Study

A. Tschoner 1 , J. Engl 1 , M. Rettenbacher 2 , M. Edlinger 2 , S. Kaser 1 , T. Tatarczyk 1 , M. Effenberger 1 , J. R. Patsch 1 , W. W. Fleischhacker 2 , C. F. Ebenbichler 1
  • 1Department of Internal Medicine I, Medical University Innsbruck, Innsbruck, Austria
  • 2Department of Biological Psychiatry, Medical University Innsbruck, Austria
Further Information

Publication History

received 11.06.2008 revised 25.08.2008

accepted 03.09.2008

Publication Date:
19 January 2009 (online)

Also available at
    Permissions and Reprints

Abstract

Background: Due to the association of second generation antipsychotics (SGAs) with weight gain and alterations of glucose and lipid homeostasis, we aimed to group six commonly prescribed SGAs into classes of differing risks.

Methods: Twenty-eight patients meeting the criteria for a diagnosis of schizophrenic disorder according to ICD-10 were assigned to monotherapy with olanzapine, clozapine, quetiapine, amisulpride, ziprasidone or risperidone. The levels of glucose and lipid metabolism were assessed before and after 28 days of treatment.

Results: Based on cluster analysis, olanzapine and clozapine were found to constitute a high-risk group for metabolic dysregulation while amisulpride, quetiapine, risperidone and ziprasidone could be assigned to a non-high-risk group. Subjects from the high-risk group displayed significant weight gain with concomitant increases of HOMA-IR, levels of insulin, total cholesterol, TG, LDL-C and leptin. No significant changes were observed in the non-high-risk group.

Conclusion: The results of this study support the conclusion of the Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes that certain SGAs are associated with a higher risk for weight gain, insulin resistance and dyslipidemia.

References

  • 1 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.  Diabet Med. 1998;  15 539-553
    CrossrefPubMedGoogle Scholar
  • 2 Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature.  J Clin Psychiatry. 2001;  62 22-31
    PubMedGoogle Scholar
  • 3 Allison DB, Mackell JA, MacDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia.  Psychiatr Serv. 2003;  54 565-567
    CrossrefPubMedGoogle Scholar
  • 4 American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity . Consensus development conference on antipsychotic drugs and obesity and diabetes.  Diabetes Care. 2004;  27 596-601
    CrossrefPubMedGoogle Scholar
  • 5 Ananth J, Venkatesh R, Burgoyne K. et al . Atypical antipsychotic induced weight gain: pathophysiology and management.  Ann Clin Psychiatry. 2004;  16 75-85
    CrossrefPubMedGoogle Scholar
  • 6 Aquila R, Emanuel M. Weight gain and antipsychotic medications.  J Clin Psychiatry. 1999;  60 336-337
    PubMedGoogle Scholar
  • 7 Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management.  Acta Psychiatr Scand. 1999;  100 3-16
    PubMedGoogle Scholar
  • 8 Baptista T, Beaulieu S. Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs?.  Can J Psychiatry. 2002;  47 742-749
    PubMedGoogle Scholar
  • 9 Baptista T, Davila A, El Fakih Y. et al . Similar frequency of abnormal correlation between serum leptin levels and BMI before and after olanzapine treatment in schizophrenia.  Int Clin Psychopharmacol. 2007;  22 205-211
    CrossrefPubMedGoogle Scholar
  • 10 Baptista T, Kin NM, Beaulieu S. et al . Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.  Pharmacopsychiatry. 2002;  35 205-219
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Beaufrere B, Morio B. Fat and protein redistribution with aging: metabolic considerations.  Eur J Clin Nutr. 2000;  54 ((Suppl. 3)) S48-S53
    PubMedGoogle Scholar
  • 12 Bromel T, Blum WF, Ziegler A. et al . Serum leptin levels increase rapidly after initiation of clozapine therapy.  Mol Psychiatry. 1998;  3 76-80
    CrossrefPubMedGoogle Scholar
  • 13 Brown RR, Estoup MW. Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine.  Int Clin Psychopharmacol. 2005;  20 105-112
    CrossrefPubMedGoogle Scholar
  • 14 Casey DE. Dyslipidemia and atypical antipsychotic drugs.  J Clin Psychiatry. 2004;  65 ((Suppl. 18)) 27-35
    PubMedGoogle Scholar
  • 15 Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome.  Nature. 2006;  444 881-887
    CrossrefPubMedGoogle Scholar
  • 16 Ebenbichler CF, Laimer M, Eder U. et al . Olanzapine induces insulin resistance: results from a prospective study.  J Clin Psychiatry. 2003;  64 1436-1439
    PubMedGoogle Scholar
  • 17 Ebenbichler C, Laimer M, Kranebitter M. et al . The soluble leptin receptor in olanzapine-induced weight gain: results from a prospective study.  Schizophr Res. 2005;  75 143-146
    CrossrefPubMedGoogle Scholar
  • 18 Eder U, Mangweth B, Ebenbichler C. et al . Association of olanzapine-induced weight gain with an increase in body fat.  Am J Psychiatry. 2001;  158 1719-1722
    CrossrefPubMedGoogle Scholar
  • 19 Engl J, Hanusch-Enserer U, Prager R. et al . The metabolic syndrome: effects of a pronounced weight loss induced by bariatric surgery.  Wien Klin Wochenschr. 2005;  117 243-254
    CrossrefPubMedGoogle Scholar
  • 20 Engl J, Laimer M, Niederwanger A. et al . Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells.  Mol Psychiatry. 2005;  10 1089-1096
    CrossrefPubMedGoogle Scholar
  • 21 Eriksson J, Franssila-Kallunki A, Ekstrand A. et al . Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus.  N Engl J Med. 1989;  321 337-343
    CrossrefPubMedGoogle Scholar
  • 22 Facchini FS, Hollenbeck CB, Jeppesen J. et al . Insulin resistance and cigarette smoking.  Lancet. 1992;  339 1128-1130
    CrossrefPubMedGoogle Scholar
  • 23 Haslam DW, James WPT. Obesity.  Lancet. 2005;  366 1197-1209
    CrossrefPubMedGoogle Scholar
  • 24 Haupt DW, Luber A, Maeda J. et al . Plasma leptin and adiposity during antipsychotic treatment of schizophrenia.  Neuropsychopharmacology. 2005;  30 184-191
    CrossrefPubMedGoogle Scholar
  • 25 Henderson DC, Cagliero E, Copeland PM. et al . Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.  Arch Gen Psychiatry. 2005;  62 19-28
    CrossrefPubMedGoogle Scholar
  • 26 Hofer A, Kemmler G, Eder U. et al . Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects.  J Clin Psychiatry. 2004;  65 932-939
    PubMedGoogle Scholar
  • 27 Hofer A, Rettenbacher MA, Edlinger M. et al . Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine.  Pharmacopsychiatry. 2007;  40 1-8
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Hummer M, Kemmler G, Kurz M. et al . Weight gain induced by clozapine.  Eur Neuropsychopharmacol. 1995;  5 437-440
    CrossrefPubMedGoogle Scholar
  • 29 Kashyap S, Belfort R, Gastaldelli A. et al . A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes.  Diabetes. 2003;  52 2461-2474
    CrossrefPubMedGoogle Scholar
  • 30 Koro CE, Fedder DO, L’Italien GJ. et al . An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.  Arch Gen Psychiatry. 2002;  59 1021-1026
    PubMedGoogle Scholar
  • 31 Kraus T, Haack M, Schuld A. et al . Body weight and leptin plasma levels during treatment with antipsychotic drugs.  Am J Psychiatry. 1999;  156 312-314
    PubMedGoogle Scholar
  • 32 Laimer M, Ebenbichler CF, Kranebitter M. et al . Olanzapine-induced hyperglycemia: role of humoral insulin resistance-inducing factors.  J Clin Psychopharmacol. 2005;  25 183-185
    CrossrefPubMedGoogle Scholar
  • 33 Larsson H, Elmstahl S, Ahren B. Plasma leptin levels correlate to islet function independently of body fat in postmenopausal women.  Diabetes. 1996;  45 1580-1584
    PubMedGoogle Scholar
  • 34 Lieberman JA, Stroup TS, MacEvoy JP. et al . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.  N Engl J Med. 2005;  353 1209-1223
    CrossrefPubMedGoogle Scholar
  • 35 Manson JE, Willett WC, Stampfer MJ. et al . Body weight and mortality among women.  N Engl J Med. 1995;  333 677-685
    CrossrefPubMedGoogle Scholar
  • 36 Matthews DR, Hosker JP, Rudenski AS. et al . Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419
    Google Scholar
  • 37 Melkersson K. Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro.  Eur Neuropsychopharmacol. 2004;  14 115-119
    CrossrefPubMedGoogle Scholar
  • 38 Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications.  Drugs. 2004;  64 701-723
    CrossrefPubMedGoogle Scholar
  • 39 Melkersson KI, Dahl ML. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses.  Psychopharmacology (Berl). 2003;  170 157-166
    CrossrefPubMedGoogle Scholar
  • 40 Melkersson KI, Hulting AL. Insulin and leptin levels in patients with schizophrenia or related psychoses – a comparison between different antipsychotic agents.  Psychopharmacology (Berl). 2001;  154 205-212
    CrossrefPubMedGoogle Scholar
  • 41 Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.  J Clin Psychiatry. 2000;  61 742-749
    PubMedGoogle Scholar
  • 42 Melkersson K, Khan A, Hilding A. et al . Different effects of antipsychotic drugs on insulin release in vitro.  Eur Neuropsychopharmacol. 2001;  11 327-332
    CrossrefPubMedGoogle Scholar
  • 43 Meyer JM. Novel antipsychotics and severe hyperlipidemia.  J Clin Psychopharmacol. 2001;  21 369-374
    CrossrefPubMedGoogle Scholar
  • 44 Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.  J Clin Psychiatry. 2007;  68 ((Suppl. 1)) 20-27
    Google Scholar
  • 45 Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.  CNS Drugs. 2005;  19 ((Suppl. 1)) 1-93
    CrossrefPubMedGoogle Scholar
  • 46 Rader DJ. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus.  Am J Med. 2007;  120 S12-18
    PubMedGoogle Scholar
  • 47 Rettenbacher MA, Ebenbichler C, Hofer A. et al . Early changes of plasma lipids during treatment with atypical antipsychotics.  Int Clin Psychopharmacol. 2006;  21 369-372
    CrossrefPubMedGoogle Scholar
  • 48 Sinha MK, Opentanova I, Ohannesian JP. et al . Evidence of free and bound leptin in human circulation. Studies in lean and obese subjects and during short-term fasting.  J Clin Invest. 1996;  98 1277-1282
    CrossrefPubMedGoogle Scholar
  • 49 Sowell MO, Mukhopadhyay N, Cavazzoni P. et al . Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.  J Clin Endocrinol Metab. 2002;  87 2918-2923
    CrossrefPubMedGoogle Scholar
  • 50 Stevens J, Cai J, Pamuk ER. et al . The effect of age on the association between body-mass index and mortality.  N Engl J Med. 1998;  338 1-7
    CrossrefPubMedGoogle Scholar
  • 51 Tandon R, Fleischhacker WW. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment.  Schizophr Res. 2005;  79 145-155
    CrossrefPubMedGoogle Scholar
  • 52 Gaal LF Van. Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity.  Eur Neuropsychopharmacol. 2006;  16 ((Suppl. 3)) S142-S148
    CrossrefPubMedGoogle Scholar
  • 53 Gaal LF Van, Mertens IL, Block CE De. Mechanisms linking obesity with cardiovascular disease.  Nature. 2006;  444 875-880
    CrossrefPubMedGoogle Scholar
  • 54 Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review.  Drug Saf. 2001;  24 59-73
    PubMedGoogle Scholar
  • 55 Wirshing DA, Wirshing WC, Kysar L. et al . Novel antipsychotics: comparison of weight gain liabilities.  J Clin Psychiatry. 1999;  60 358-363
    CrossrefPubMedGoogle Scholar
  • 56 Wu RR, Zhao JP, Liu ZN. et al . Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.  Psychopharmacology (Berl). 2006;  186 572-578
    CrossrefPubMedGoogle Scholar
  • 57 Zhang Y, Proenca R, Maffei M. et al . Positional cloning of the mouse obese gene and its human homologue.  Nature. 1994;  372 425-432
    CrossrefPubMedGoogle Scholar
  • 58 Zimmet PZ. Kelly West Lecture 1991. Challenges in diabetes epidemiology – from West to the rest.  Diabetes Care. 1992;  15 232-252
    PubMedGoogle Scholar

Correspondence

C. F. EbenbichlerMD 

Department of Internal Medicine I

Medical University Innsbruck

Anichstraße 35

6020 Innsbruck

Austria

Phone: +43/512/504/285 37

Fax: +43/512/504/285 39

Email: Christoph.Ebenbichler@i-med.ac.at

      >